2024-02-04 09:21:56 ET
Summary
- AstraZeneca is one of the fastest-growing pharmaceutical companies.
- On February 8, 2024, the company will publish financial results for the 4th quarter of 2023.
- From a broader perspective, AstraZeneca's EPS is expected to continue to grow through 2026.
- Sales of most of AstraZeneca's cancer blockbusters have continued to grow at a rapid pace in recent years.
- So, sales of Imfinzi were $1.13 billion in the third quarter of 2023, up 52.8% year-over-year.
AstraZeneca ( AZN ) is one of the fast-growing pharmaceutical companies that has played a significant role in saving the lives of COVID-19 patients and is known worldwide for innovative medicines such as Lynparza, Farxiga, and Imfinzi.
Thesis
Ahead of AstraZeneca's fourth-quarter 2023 financial results next week , its share price continues to fluctuate near an uptrend line, the first sign that traders and investors remain optimistic regarding its business development in 2024....
Read the full article on Seeking Alpha
For further details see:
AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth